Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions-Reference-Cited by-同舟云学术

Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions

Published:2021-10 Issue: Volume:165 Page:105932
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

Lang Jennifer,Vincent Ludwig,Chenel Marylore,Ogungbenro Kayode,Galetin Aleksandra

Funder

Institut de Recherches Servier

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference84 articles.

1. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans;Blech;Drug Metab. Dispos.,2008

2. Physiological parameter values for physiologically based pharmacokinetic models;Brown;Toxicol. Ind. Health,1997

3. Phase 0/microdosing approaches: time for mainstream application in drug development?;Burt;Nat. Rev. Drug Discov.,2020

4. Recommendations for the design of clinical drug–drug interaction studies with itraconazole using a mechanistic physiologically-based pharmacokinetic model;Chen;CPT Pharmacomet. Syst. Pharmacol.,2019

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the relative contribution of CYP3A-and P-gp-mediated pathways to the overall disposition and drug-drug interaction of dabigatran etexilate using a comprehensive mechanistic physiological-based pharmacokinetic model;Frontiers in Pharmacology;2024-03-07

2. Membrane transporters in drug development and as determinants of precision medicine;Nature Reviews Drug Discovery;2024-01-24

3. Physiologically based pharmacokinetic (PBPK) modelling of oral drug absorption in older adults – an AGePOP review;European Journal of Pharmaceutical Sciences;2023-09

4. The Potentially Significant Role of CYP3A-Mediated Oxidative Metabolism of Dabigatran Etexilate and Its Intermediate Metabolites in Drug-Drug Interaction Assessments Using Microdose Dabigatran Etexilate;Drug Metabolism and Disposition;2023-05-25

5. Predicting transporter mediated drug–drug interactions via static and dynamic physiologically based pharmacokinetic modeling: A comprehensive insight on where we are now and the way forward;Biopharmaceutics & Drug Disposition;2022-12-14